Spectrum Pharmaceutecals Inc (SPPI)

[antihama]

I just checked. SPPI owns ~10M shares at the end of 2016 which makes it around 16.7% ownership and they have the right to maintain their post investment ownership. So I can see them going back up to 20% at the right time. Per the Annual Report

On September 17, 2014, we executed three product out-license agreements with a perpetual term (collectively, the “CASI Out-License”) with CASI Pharmaceuticals, Inc. (“CASI”), a publicly-traded biopharmaceutical company (NASDAQ: CASI) with a primary focus on the China market. Under the CASI OutLicense, we granted CASI the exclusive rights to distribute two of our commercialized oncology drugs, ZEVALIN and MARQIBO, and our Phase 3 drug candidate, EVOMELA (“CASI Out-Licensed Products”) in greater China (which includes Taiwan, Hong Kong and Macau). In return, we received CASI equity for the rights related to ZEVALIN and EVOMELA and a secured promissory note for the rights related to MARQIBO. Additionally, under certain conditions which generally expire on September 17, 2019 , we have a right to receive additional CASI common stock in order to maintain our post-investment ownership percentage if CASI issues additional securities. In February 2016, July 2016, and October 2016, we acquired an additional 1.7 million , 1.1 million and 1.8 million common shares of CASI at par value, respectively, resulting in our holding of approximately 10 million common shares as of December 31, 2016 .
CASI will be responsible for the development and commercialization of these three drugs, including the submission of import drug registration applications to regulatory authorities and conducting any confirmatory clinical studies in greater China. We will provide CASI with future commercial supply of the CASI OutLicensed Products under typical market terms.